Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Robert Laszewski on the Effect of ACA on Urology Practices

January 9th 2014

Robert Laszewski, President, Health Policy and Strategy Associates, LLC, discusses the effects of the Affordable Care Act (ACA) on urology practices.

Dr. Reyna on LUGPA Member Ancillary Services

January 7th 2014

Juan A. Reyna, MD, President, LUGPA, discusses in-office ancillary services among LUGPA members.

Dr. Concepcion on Urologist Practice Challenges

January 3rd 2014

Raoul Concepcion, MD, director of clinical research, urologic surgeon, Urology Associates, PC, in Nashville, Tennessee discusses some of the challenges that independent and community urologists face.

Failed Studies Provide Clues in Renal Cell Carcinoma

December 23rd 2013

The mTOR inhibitor temsirolimus has limited utility in combination with frontline bevacizumab and as a second-line single agent for patients with metastatic renal cell carcinoma

Hyponatremia Associated With Poor Prognosis in mRCC

December 19th 2013

Hyponatremia is significantly associated with worse outcomes in patients with metastatic renal cell carcinoma (mRCC) who received treatment with VEGF- and mTOR-targeted agents

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

December 5th 2013

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

RCC Care Evolving With Targeted and Novel Agents

December 4th 2013

With seven targeted therapies approved for metastatic renal cell carcinoma, researchers and drug developers are now focusing on understanding the best way to sequence these therapies and on identifying predictive biomarkers of response.

Dr. Pal on Sequencing Nivolumab in RCC

December 2nd 2013

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing nivolumab in the treatment of renal cell carcinoma.

Dr. Balar on Immunotherapy in Bladder Cancer

November 25th 2013

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the potential of immunotherapy agents as treatment for bladder cancer.

Treating Renal Cell Carcinoma in 2013: An Interview With Sumanta Kumar Pal, MD

November 19th 2013

Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.

Dr. Galsky on Ipilimumab in Bladder Cancer

November 15th 2013

Matthew D. Galsky, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, explains the mechanism of action of ipilimumab in bladder cancer.

Urologist Ownership of Imaging Centers Affects Self-Referral Rates

November 14th 2013

Urologists who treat men with prostate cancer are 2.5 times more likely to refer patients to intensity-modulated radiation therapy centers, especially if they have a financial stake in the IMRT center.

Promising Immune Activation Found in mRCC for AGS-003

November 14th 2013

The investigational autologous dendritic cell vaccine AGS-003 successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma

Dr. Pal on Adjuvant Therapy of Renal Cell Carcinoma

November 13th 2013

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).

Everolimus Offers Benefit in Papillary Renal Cell Carcinoma

November 13th 2013

Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.

Lessons From the Great Lakes

October 22nd 2013

We as physicians, especially surgeons, tend to operate on the same principle: When things go bad, especially when revenue goes down, we just work harder and see more patients, with the expectation that it will correct and we can maintain.

Dr. Schmidinger on RCC Therapy Toxicity Management

October 21st 2013

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).

In a Surprise Finding, Gene Mutation Found Linked to Low-Risk Bladder Cancer

October 16th 2013

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

Dr. GrÃ¼nwald on Tumor Remission in RCC

October 15th 2013

Viktor GrÃ¼nwald, MD, PhD, an attending physician at the Hannover Medical School, discusses tumor remission in patients with renal cell carcinoma (RCC).

Dr. George on Sunitinib in Renal Cell Carcinoma

October 10th 2013

Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).